A top an­a­lyst spot­lights a wave of biotech star­tups look­ing to cat­a­pult on­to Nas­daq — or get bought out

There should be no short­age of biotech com­pa­nies look­ing to file an IPO — or ex­e­cute a buy­out deal — in 2020 and 2021.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters